Please ensure Javascript is enabled for purposes of website accessibility

Why Co-Diagnostics Stock Is Soaring 15.5% Higher Today

By Keith Speights - Apr 16, 2020 at 11:40AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's COVID-19 test received a key validation.

What happened

Shares of Co-Diagnostics (CODX -1.64%) were soaring 15.5% higher as of 11:22 a.m. EDT on Thursday. The big jump came after the company announced that its COVID-19 test technology has been validated for use on saliva samples.

So what

Anyone who saw President Trump's press conference around a month ago after he was tested for COVID-19 heard the president say "there was nothing pleasant" about the test. Initial COVID-19 testing was done using nasal swabs. And they're not pleasant.

COVID-19 printed in white and red against a blue background.

Image source: Getty Images.

But COVID-19 tests that use saliva samples are much more pleasant. For those tests, individuals need only "swish and gargle," Co-Diagnostics CEO Dwight Egan said.

OraolDNA Labs' validation of Co-Diagnostics' COVID-19 test with saline oral rinse samples is good news for the company. OralDNA Labs also informed the U.S. Food and Drug Administration (FDA) that it plans to use Co-Diagnostics' validated test in its lab.

Co-Diagnostics' Logix Smart COVID-19 test is currently available for use in all labs certified under Clinical Laboratory Improvement Amendments (CLIA) under the FDA's Emergency Use Authorization program.

Now what

The COVID-19 outbreak has been a major catalyst for Co-Diagnostics, with its shares skyrocketing more than 1,100% so far this year. However, the company isn't profitable yet. The stock is now trading at an astronomically high price-to-sales multiple. Co-Diagnostics' revenue is likely to grow tremendously, but it remains to be seen if that growth will be enough to justify the stock's steep valuation.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
$5.40 (-1.64%) $0.09

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.